These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 8748320

  • 1. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
    Sharma A, Straubinger RM, Ojima I, Bernacki RJ.
    J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
    [Abstract] [Full Text] [Related]

  • 2. Update on taxane development: new analogs and new formulations.
    Yared JA, Tkaczuk KH.
    Drug Des Devel Ther; 2012 Dec; 6():371-84. PubMed ID: 23251087
    [Abstract] [Full Text] [Related]

  • 3. Preclinical antitumor activity of two novel taxanes.
    Rose WC, Fairchild C, Lee FY.
    Cancer Chemother Pharmacol; 2001 Dec; 47(2):97-105. PubMed ID: 11269747
    [Abstract] [Full Text] [Related]

  • 4. Progress in the development of alternative pharmaceutical formulations of taxanes.
    Nuijen B, Bouma M, Schellens JH, Beijnen JH.
    Invest New Drugs; 2001 May; 19(2):143-53. PubMed ID: 11392448
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q, Vincent M, Logan D, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [Abstract] [Full Text] [Related]

  • 13. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
    Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ.
    J Med Chem; 1996 Sep 27; 39(20):3889-96. PubMed ID: 8831755
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA.
    Clin Breast Cancer; 2000 Apr 27; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
    Vanhoefer U, Cao S, Harstrick A, Seeber S, Rustum YM.
    Ann Oncol; 1997 Dec 27; 8(12):1221-8. PubMed ID: 9496387
    [Abstract] [Full Text] [Related]

  • 19. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
    Nicoletti MI, Lucchini V, D'Incalci M, Giavazzi R.
    Eur J Cancer; 1994 Dec 27; 30A(5):691-6. PubMed ID: 7915909
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.